Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
McKeage K, Plosker GL, Siddiqui MAA. Lubiprostone. Drugs 2006; 66(6): 873–79
Schiller LR. Lubiprostone: a viewpoint. Drugs 2006; 66(6): 880–1
Camilleri M. Lubiprostone: a viewpoint. Drugs 2006; 66(6): 881
Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004 Nov; 287(5): C1173–83
Sucampo Pharmaceuticals Inc. Amitiza (lubiprostone) prescribing information (revised March 2006) [online]. Available from URL: http://www.amitiza.com/resources/pi.pdf [Accessed 2006 Apr 10]
Johanson JF, Gargano MA, Holland PC, et al. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation [abstract no. 372]. Gastroenterology 2003 Apr; 124(4 Suppl. 1): A48
Johanson JF, Gargano MA, Holland PC, et al. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primary efficacy [abstract no. 896]. Am J Gastroenterol 2005 Sep; 100Suppl. 9: s328–9
Rights and permissions
About this article
Cite this article
Lubiprostone: profile report. Drugs Ther. Perspect 22, 5–6 (2006). https://doi.org/10.2165/00042310-200622090-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200622090-00002